Michael R. Hayden, Director at AbCellera Biologics Inc. (ABCL), bought 46,387 shares at $10.37 ($481K) on 2026-08-12, disclosed to the SEC on 2026-08-14.
Open-market purchase of $481k ABCL by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| IONS | BUY | 2025-05-02 | $478K | — | Filing → |
| IONS | BUY | 2024-12-26 | $272K | — | Filing → |
| ABCL | BUY | 2023-09-26 | $98K | — | Filing → |